# OnCo record poziotinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/poziotinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "poziotinib" ;
  schema:name "Poziotinib"@en ;
  schema:alternateName "HM781-36B"@en, "NOV120101"@en ;
  schema:description "Poziotinib was a tablet designed to fit the awkward shape of HER2 and EGFR exon 20 mutations in lung cancer. It shrank tumours in some patients but caused severe rash and diarrhoea, and the FDA declined to approve it in 2022."@en ;
  schema:url <https://onco.cc/drugs/poziotinib/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Poziotinib> ;
  schema:citation <https://en.wikipedia.org/wiki/Poziotinib> ;
  onco:status "negative" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "Oral irreversible pan-HER tyrosine kinase inhibitor" ;
  onco:related <https://onco.cc/drugs/pyrotinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:cancers <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/spectrum-pharmaceuticals/> .